Abstract
BackgroundFibrinogen alpha C chain 5.9 kDa fragment (FIC5.9) is a new serum biomarker for chronic hepatitis that was discovered by proteomics analysis. Previous studies have shown that FIC5.9 is derived from the C-terminal region of fibrinogen alpha chain and the serum levels of FIC5.9 decrease in chronic hepatitis. It also have been reported that FIC5.9 cannot be detected in the blood stream of the systemic circulation and it is released from fibrinogen during blood clotting in collecting tube. However, the mechanism of FIC5.9 releasing from fibrinogen is unclear.MethodsWe formulated a hypothesis that FIC5.9 is released by enzymes that are activated by post-blood collection and may be coagulation and fibrinolysis factors. In this study, we analyzed the mechanisms of FIC5.9 releasing from fibrinogen in healthy blood.ResultsOur analysis showed that thrombin acts as an initiator for FIC5.9 releasing, and that mainly plasmin cleaves N-terminal end of FIC5.9 and neutrophil elastase cleave C-terminal end of FIC5.9.ConclusionFIC5.9 reflects minute changes in coagulation and fibrinolysis factors and may be associated with pathological conditions.Electronic supplementary materialThe online version of this article (doi:10.1186/s12014-016-9129-6) contains supplementary material, which is available to authorized users.
Highlights
Fibrinogen alpha C chain 5.9 kDa fragment (FIC5.9) is a new serum biomarker for chronic hepatitis that was discovered by proteomics analysis
Fibrinogen alpha C chain 5.9 kDa fragment (FIC5.9) is a new serum marker for chronic hepatitis that was discovered in samples from alcoholic liver disease using SELDI-TOF MS [4]
LC–MS/MS analysis of degradation products of fibrinogen in vitro To reconfirm that FIC5.9 is released from fibrinogen in the serum collection tube during blood clotting [8], we studied FIC5.9 releasing analysis using coagulationdeficient plasma
Summary
Fibrinogen alpha C chain 5.9 kDa fragment (FIC5.9) is a new serum biomarker for chronic hepatitis that was discovered by proteomics analysis. Previous studies have shown that FIC5.9 is derived from the C-terminal region of fibrinogen alpha chain and the serum levels of FIC5.9 decrease in chronic hepatitis. Many biomarkers have been discovered by proteomics analysis, but fewer have been developed for clinical use [1, 2]. Fibrinogen alpha C chain 5.9 kDa fragment (FIC5.9) is a new serum marker for chronic hepatitis that was discovered in samples from alcoholic liver disease using SELDI-TOF MS [4]. The results showed that the serum level of FIC5.9 is significantly decreased in Kikuchi et al Clin Proteom (2016) 13:27 we tested the hypothesis that FIC5.9 is released by these enzymes in apparently healthy subjects
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
